Home » Newsletters » BioWorld Science

BioWorld Science

March 15, 1996

View Archived Issues

Abbott and Purdue Pharma to copromote analgesic

Zeneca acquires antimigraine drug

Antipsoriatic treatment in development at Immune Response

Human Genome Sciences claims novel wound-healing agents

Human lactoferrin produced in transgenic animals

UR-9751 dropped from development

Antiviral drugs from Glaxo Wellcome

Glaxo Wellcome, Quidel collaborate on flu management

Lidakol clinical trial update

Hoechst claims RTase inhibitors

FDA approves HIV drug

Avid may license DMP-450 from DuPont Merck

British Biotech abandons HIV candidate

Nagrestip tested for use in HIV

Cel-Sci's AIDS vaccine demonstrates efficacy

MDX-240 promising in HIV trials

Alpha Leukoferon to be tested in HIV-infected hemophiliacs

Cidofovir approval recommended by committee

Nitazoxanide advances in phase II

Neupogen approved for AIDS-related indication

U.S. phase III trials of Remune begin

Lilly reports drugs for osteoarthritis

Glaxo Wellcome formalizes development status of arthritis drug

Colloral dose refinement study underway

T Cell Sciences, ArQule to collaborate on T cell modulators

AI-502 slated to enter clinical trials

Axis Genetics reports on vaccine technology

AllerVax codevelopment terminated by HMR

Novel platinum compound reported

KI-30606, anticancer platinum conjugate reported for first time

JM-473 candidate for clinical development

Andrulis' platinum-polymer complex

MGI-114 enters phase I

University of Bradford reports on cytotoxic indoloquinone

Distamycin analogue from P&U shows cytotoxic effects

Aminopterin resurrected for ALL

Kirin anticancer drug in clinical trials

Inex reports on liposomal vincristine development

MEN-10746 selected for development

MEN-10755 named as candidate for clinical study

PK1 to enter phase II

European clinical trial results with irinotecan reported

FDA gives green light to Immunex's etoposide

Paclitaxel derivatives from Bristol-Myers Squibb

More approvals for Taxotere

New antimitotic drugs from Pharmacia & Upjohn

Techniclone establishes distribution agreement for Oncolym

Virogenetics cancer vaccine in phase I/II trials

IDEC-C2B8 development update

Marimastat enters phase II in U.S.

Glaxo Wellcome reports antitumor drugs

OM-174 shows in vivo antitumor activity

Eisai describes antitumor sulfonamide

MethylGene established to study antisense drugs for cancer indications

Xenova to evaluate MDR modulator in phase I

Multidrug resistance modulator from Pfizer

FDA approves expanded labeling for Ethyol

AI-300 for uveitis

Pharmos completes loteprednol etabonate trial

Sanofi claims CCK-A agonists for obesity

Hematopoietic research at Temple University

rHb 1.1 safety demonstrated in surgery patients

New Hemosol division to focus on blood substitutes

HemaSure's SteriPath system closer to IDE filing

FDA approves Medtronic's blood processing system

Xytronyx to submit periodontal tissue monitor to FDA for approval

AMDL signs Chinese distribution agreement for DR-70

Myriad Genetics concentrates on breast cancer detection

Gull Labs presents GeneSTAR diagnostic system

Patent issued on technology for detecting susceptibility to cancer

FDA approves HIV screening kit

Sonus completes enrollment in EchoGen trial

Cephalon reports modafinil study results

Arris, P&U collaborate on combinatorial chemistry

CIMA signs agreements for OraSolv drug delivery technology

Bayer acquires rights to CryoLife technology

BASF to acquire majority stake in Hokuriku

Elan, Athena to merge

Sparta acquires Lexin

Yissum claims novel anticonvulsants

BB-3644 in development for multiple sclerosis

Lexipafant evaluated for MS treatment

Myloral development update

Yamanouchi claims PCP antagonist for dementia

Cyclahexadiene derivatives reported by Bayer for AD

Antioxidants to treat Alzheimer's disease?

Pierre Fabre reports antioxidants with neurologic activity

Astra antioxidants for hypoxia

Alpha2-adrenoceptor antagonists with neuroprotective effects

Solvay acquires betahistine rights

Uriach PAF antagonist/antihistamine for allergic rhinitis

Nasacort effective in hay fever sufferers

Uriach discontinues antiasthma drug

Fujisawa claims PDE IV/TNF inhibitors

Terumo TxA2/LTD4 antagonists for asthma

Lexipafant asthma trial update

Lercanidipine approval imminent

Uriach antihypertensive drug update

Kyowa Hakko reports endothelin antagonists

Ciba-Geigy claims renin inhibitors

Potassium channel openers from Nippon Kayaku

Kirin to codevelop antiischemic drug candidate

Class III antiarrhythmics from Mitsui Toatsu

First introduction for certoparin

Fibrinogen antagonists from E. Merck

VML-252 for hyperphosphatemia

Synsorb develops drug for hemorrhagic colitis

Anti-Helicobacter agents from Janssen

Takeda targets Helicobacter pylori

Teikoku Hormone claims antiulcer drugs

Dosmalfate pending Spanish approval

Calixarene derivatives from University of Alabama

Zadaxin effective in HBV patients

Lexipafant for pancreatitis

Antidiabetic drugs claimed by Tanabe Seiyaku

Sankyo reports drugs for diabetes

AI-401 slated to enter phase II

Tsumura Juntendo research into aldose reductase inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...